SWEEP
25.5.2023 00:02:32 CEST | Business Wire | Press release
Sweep, the leading carbon and ESG management platform, today launched Sweep for Compliance, the first solution for reliable, transparent, and audit-ready reporting in compliance with the EU’s new Corporate Sustainability Reporting Directive (CSRD).
By 2025, an estimated 50,000 European Union businesses and at least 10,000 EU-based foreign companies will be falling under the scope of the CSRD, requiring them to communicate their 2024 extra-financial information. Globally, a rising number of sustainability disclosure regulations demand companies and financial institutions to track and publicly communicate new sets of data. If companies fail to act, they face compliance risks, such as financial sanctions, legal penalties, and damaging greenwashing accusations.
But, measuring ESG and carbon data is complex and time consuming without the right technology. Two-thirds (65%) of French business leaders believe their organization is not sufficiently prepared to meet ESG objectives, nor to fulfill regulatory requirements according to Workiva. Sweep for Compliance helps businesses easily comply with the right ESG, carbon, and regulatory disclosure requirements using advanced data analytics and reporting requirements directly embedded into the platform.
“In 2023, data collection can’t be a bottleneck for companies to track and improve their positive impact. Monitoring extra financial data is now a crucial business issue as European sustainability regulations become more stringent. Sweep for Compliance gives CFOs, CSOs, and auditors the most advanced tools to measure carbon and ESG data and comply with upcoming legislation,” says Rachel Delacour, CEO and Cofounder at Sweep.
Sweep for Compliance streamlines the disclosure exercise, from data gathering and quality checks, traceability and monitoring, to generating insights and in-depth reports. With up to 50% time saved in the auditing process, it ensures consistent, verified, and compliant ESG and carbon data reporting in one click. It’s the only solution on the market to help companies get ready and stay on track with disclosure requirements.
“With the growing number of sustainability regulations and stakeholder demands for transparency, companies are under pressure to accurately communicate their impact. By working with tech partners like Sweep, large organizations can streamline the collection, monitoring, and reporting of their non financial data in one single place,” says Jérémie Joos, Co-Head of ESG Center of Excellence at KPMG France.
Sweep is the trusted data partner for companies such as pet food giant Royal Canin and global leader in connected health company Withings. After launching Sweep for Supply Chain in February 2023, the company is committed to creating the best solutions for organizations to improve their ESG and carbon impact while avoiding non-compliance damages. That’s how they can lead – and thrive – in the future low carbon economy.
• • •
About Sweep
Sweep helps businesses track and act on their carbon and ESG data, so they can become Forever Companies.
The data-driven platform makes it easy to understand, manage, and report carbon emissions and ESG metrics. Powerful collaboration features and user-focused design empower staff and entire value chains to grow a sustainable business. And with all the data in one place, its advanced analytics offer comprehensive insights and deliver auditable reports aligned with the latest sustainability regulations and frameworks.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition, France Invest, and The International Emissions Trading Association. It was selected to join FrenchTech Next 120/40 program and was named “Europe’s fastest growing scale up by Financial Times’ Sifted.
For more information, visit sweep.net
About KPMG France
KPMG in France – market leader in Audit and Consulting – is a 11,000-strong team of professionals dedicated to creating a new prosperity that's set to enhance companies of all sizes. In 2022, a century after its founding, KPMG became a "société à mission” (Purpose-driven company). Its purpose is to work and innovate with passion, to build trust, to combine performance and responsibility and to develop talent at the heart of the economy, territories and society. Thanks to its multidisciplinary model, KPMG combines industry, ESG and digital expertise by relying on its ESG Center of Excellence and its community of 1 000 digital experts to support the growth and transformation projects of its 100,000 clients all over the country.
For more information, visit kpmg.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom